AQR Capital Management
MIST icon

AQR Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

AQR Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$20.2K – 3798
2025
Q4 		$20.2K Hold
10,000
– – ﹤0.01% 3548
2025
Q3 		$20K Buy
+10,000
New +$17.6K ﹤0.01% 3448

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

AQR Capital Management's MIST Position: Q1 2026 in Review

AQR Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q1 2026, closing a stake of 10,000 shares — an estimated $20.2K sold.

AQR Capital Management first reported a position in MIST in Q3 2025 and held it in 2 quarters. The position peaked at $20.2K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • AQR Capital Management reported no remaining Milestone Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AQR Capital Management sold 10,000 Milestone Pharmaceuticals shares in Q1 2026, an estimated $20.2K.
  • AQR Capital Management first reported a position in Milestone Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • AQR Capital Management's Milestone Pharmaceuticals position peaked at $20.2K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.